This study is evaluating an oral investigational medication (solriamfetol) in adults with BED. Solriamfetol is approved by the FDA for people who have excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea (OSA), which are sleep-related disorders. Solriamfetol is an investigational treatment for BED, meaning it has not yet been approved by any health authority for the treatment of BED.
The ENGAGE study is looking for adults who:
Are 18-55 years old
Currently experience symptoms of Binge Eating Disorder (BED) including recurrent episodes of consuming excessive amounts of food accompanied by a sense of loss of control over the eating
Experience at least 2 binge eating episodes per week for the last 6 months